Effects of cisplatin on surgically induced endometriosis in a rat model

Li,Zhanfei; Liu,Huibing; Lang,Jinghe; Zhang,Guoru; He,Zhengxing

doi:10.3892/ol.2018.9275

Effects of cisplatin on surgically induced endometriosis in a rat model

Authors:
- Zhanfei Li
- Huibing Liu
- Jinghe Lang
- Guoru Zhang
- Zhengxing He
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing 100005, P.R. China
Published online on: August 7, 2018 https://doi.org/10.3892/ol.2018.9275
Pages: 5282-5290
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Research has strongly suggested that the features of endometriosis serve as a precursor lesion of ovarian cancer. Cisplatin (CDDP) is the preferred drug against these cancer types. The present study investigated the effects of CDDP on surgically induced endometriosis in a rat model. Endometriosis was surgically induced by the autologous transplantation of endometrial tissue. A total of 36 model rats were randomly divided into three groups. The rats in Group 1 (control group, n=12) received no medication. The rats in Group 2 (n=12) and Group 3 (n=12) were administered 35 mg/m2 CDDP and 70 mg/m2 CDDP, respectively, every four days. All rats were treated for a total of 24 days. The growth and histologic scores of the implants were calculated. The expression of protein markers, including vascular endothelial growth factor (VEGF), aromatase P450 (P450arom), transforming growth factor‑β (TGF‑β) and matrix metalloproteinase (MMP)‑2, were assessed using immunohistochemistry, an enzyme‑linked immunosorbent assay and western blot analysis. Following CDDP treatment, the mean implant sizes were significantly reduced in Groups 2 and 3 compared with the control group (P=0.01). The mean histologic scores were also significantly lower in Groups 2 and 3. Furthermore, the protein expression of VEGF, P450arom, TGF‑β and MMP‑2 was significantly lower in Groups 2 and 3 when compared with the control group. A loss of hair was observed in 4 rats, which only occurred in Group 3. A dose‑dependent effect was observed in the two CDDP‑treated groups. In conclusion, the expression of proliferation‑ and angiogenesis‑associated proteins was significantly lower following treatment with CDDP. CDDP caused a significant regression in the size of the endometriotic implants and induced atrophy of these lesions in rats.

View Figures

View References

1	Nothnick WB: The emerging use of aromatase inhibitors for endometriosis treatment. Reprod Biol Endocrinol. 9:872011. View Article : Google Scholar : PubMed/NCBI
2	Bulun SE, Imir G, Utsunomiya H, Thung S, Gurates B, Tamura M and Lin Z: Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol. 95:57–62. 2005. View Article : Google Scholar : PubMed/NCBI
3	Bedaiwy MA, Allaire C and Alfaraj S: Long-term medical management of endometriosis with dienogest and with a gonadotropin-releasing hormone agonist and add-back hormone therapy. Fertil Steril. 107:537–548. 2017. View Article : Google Scholar : PubMed/NCBI
4	Surrey ES and Hornstein MD: Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: Long-term follow-up. Obstet Gynecol. 99:709–719. 2002. View Article : Google Scholar : PubMed/NCBI
5	Meng Q, Sun W, Jiang J, Fletcher NM, Diamond MP and Saed GM: Identification of common mechanisms between endometriosis and ovarian cancer. J Assist Reprod Genet. 28:917–923. 2011. View Article : Google Scholar : PubMed/NCBI
6	Wang S, Qiu L, Lang JH, Shen K, Huang HF, Pan LY, Wu M, Yang JX and Guo LN: Prognostic analysis of endometrioid epithelial ovarian cancer with or without endometriosis: A 12-year cohort study of Chinese patients. Am J Obstet Gynecol. 209:241 e241–e249. 2013. View Article : Google Scholar
7	Li F, Tie R, Chang K, Wang F, Deng S, Lu W, Yu L and Chen M: Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: A meta-analysis. BMC Cancer. 12:2582012. View Article : Google Scholar : PubMed/NCBI
8	Augoulea A, Alexandrou A, Creatsa M, Vrachnis N and Lambrinoudaki I: Pathogenesis of endometriosis: The role of genetics, inflammation and oxidative stress. Arch Gynecol Obst. 286:99–103. 2012. View Article : Google Scholar
9	Olovsson M: Immunological aspects of endometriosis: An update. Am J Reprod Immunol. 66 Suppl 1:S101–S104. 2011. View Article : Google Scholar
10	Ogawa S, Kaku T, Amada S, Kobayashi H, Hirakawa T, Ariyoshi K, Kamura T and Nakano H: Ovarian endometriosis associated with ovarian carcinoma: A clinicopathological and immunohistochemical study. Gynecol Oncol. 77:298–304. 2000. View Article : Google Scholar : PubMed/NCBI
11	Somigliana E, Vigano P, Parazzini F, Stoppelli S, Giambattista E and Vercellini P: Association between endometriosis and cancer: A comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol. 101:331–341. 2006. View Article : Google Scholar : PubMed/NCBI
12	Vlahos NF, Kalampokas T and Fotiou S: Endometriosis and ovarian cancer: A review. Gynecol Endocrinol. 26:213–219. 2010. View Article : Google Scholar : PubMed/NCBI
13	Aris A: Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res. 3:22010. View Article : Google Scholar : PubMed/NCBI
14	Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE and Westhoff CL: Ovarian cancer risk associated with varying causes of infertility. Fertil Steril. 82:405–414. 2004. View Article : Google Scholar : PubMed/NCBI
15	Siufi Neto J, Kho RM, Siufi DF, Baracat EC, Anderson KS and Abrao MS: Cellular, histologic, and molecular changes associated with endometriosis and ovarian cancer. J Minim Invasive Gynecol. 21:55–63. 2014. View Article : Google Scholar : PubMed/NCBI
16	Zhao C, Wu LS and Barner R: Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: Clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development. J Cancer. 2:94–106. 2011. View Article : Google Scholar : PubMed/NCBI
17	Bookman MA: Optimal primary therapy of ovarian cancer. Ann Oncol. 27 Suppl 1:i58–i62. 2016. View Article : Google Scholar : PubMed/NCBI
18	da Costa Miranda V, de Souza Fêde ÂB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, de Paula Carvalho J, Filho EA, de Freitas D and Del Pilar Estevez Diz M: Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness. Gynecol Oncol. 132:287–291. 2014. View Article : Google Scholar : PubMed/NCBI
19	Yu X, Zheng H, Chan MT and Wu WK: Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer. Am J Cancer Res. 7:1769–1778. 2017.PubMed/NCBI
20	Wang QE, Milum K, Han C, Huang YW, Wani G, Thomale J and Wani AA: Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells. Mol Cancer. 10:242011. View Article : Google Scholar : PubMed/NCBI
21	Woo MG, Xue K, Liu J, McBride H and Tsang BK: Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking. J Biol Chem. 287:3963–3975. 2011. View Article : Google Scholar : PubMed/NCBI
22	Ingelmo JM, Quereda F and Acien P: Effect of human interferon-alpha-2b on experimental endometriosis in rats: Comparison between short and long series of treatment. Eur J Obst Gynecol Reprod Biol. 167:190–193. 2013. View Article : Google Scholar
23	Sun J, Jin C, Wu H, Zhao J, Cui Y, Liu H, Wu L, Shi Y and Zhu B: Effects of electro-acupuncture on ovarian P450arom, P450c17α and mRNA expression induced by letrozole in PCOS rats. PLoS One. 8:e793822013. View Article : Google Scholar : PubMed/NCBI
24	Simsek Y, Celik O, Karaer A, Gul M, Yılmaz E, Koc O, Colak C, Zengin S and Aydin NE: Therapeutic efficiency of Atosiban, an oxytocin receptor blocking agent in the treatment of experimental endometriosis. Arch Gynecol Obstet. 286:777–783. 2012. View Article : Google Scholar : PubMed/NCBI
25	Körbel C, Menger MD and Laschke MW: Size and spatial orientation of uterine tissue transplants on the peritoneum crucially determine the growth and cyst formation of endometriosis-like lesions in mice. Hum Reprod. 25:2551–2558. 2010. View Article : Google Scholar : PubMed/NCBI
26	Spiers DE and Candas V: Relationship of skin surface area to body mass in the immature rat: A reexamination. J Appl Physiol Respir Environ Exerc Physiol. 56:240–243. 1984.PubMed/NCBI
27	Ceyhan ST, Onguru O, Fidan U, Ide T, Yaman H, Kilic S and Baser I: Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model. Eur J Obstet Gynecol Reprod Biol. 154:100–104. 2011. View Article : Google Scholar : PubMed/NCBI
28	Keenan JA, Williams-Boyce PK, Massey PJ, Chen TT, Caudle MR and Bukovsky A: Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil Steril. 72:135–141. 1999. View Article : Google Scholar : PubMed/NCBI
29	Edwards AK, Nakamura DS, Virani S, Wessels JM and Tayade C: Animal models for anti-angiogenic therapy in endometriosis. J Reprod Immunol. 97:85–94. 2013. View Article : Google Scholar : PubMed/NCBI
30	Li Z, Liu H, He Z, Zhang G and Lang J: Effects of cisplatin and letrozole on surgically induced endometriosis and comparison of the two medications in a rat model. Eur J Pharm Sci. 93:132–140. 2016. View Article : Google Scholar : PubMed/NCBI
31	Stanic AK, Kim M, Styer AK and Rueda BR: Dendritic cells attenuate the early establishment of endometriosis-like lesions in a murine model. Reprod Sci. 21:1228–1236. 2014. View Article : Google Scholar : PubMed/NCBI
32	Aydin Y, Atis A, Uludag S, Tezer I, Sakiz D, Acar H and Toklu A: Remission of endometriosis by hyperbaric oxygen treatment in rats. Reprod Sci. 18:941–947. 2011. View Article : Google Scholar : PubMed/NCBI
33	Mansour G, Sharma RK, Agarwal A and Falcone T: Endometriosis-induced alterations in mouse metaphase II oocyte microtubules and chromosomal alignment: A possible cause of infertility. Fertil Steril. 94:1894–1899. 2010. View Article : Google Scholar : PubMed/NCBI
34	Chen QH, Zhou WD, Pu DM, Huang QS, Li T and Chen QX: 15-Epi-lipoxin A(4) inhibits the progression of endometriosis in a murine model. Fertil Steril. 93:1440–1447. 2010. View Article : Google Scholar : PubMed/NCBI
35	Sharpe-Timms KL: Using rats as a research model for the study of endometriosis. Ann NY Acad Sci. 955:318–406. 2002. View Article : Google Scholar : PubMed/NCBI
36	Osteen KG, Yeaman GR and Bruner-Tran KL: Matrix metalloproteinases and endometriosis. Semin Reprod Med. 21:155–164. 2003. View Article : Google Scholar : PubMed/NCBI
37	Griffioen AW and Molema G: Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 52:237–268. 2000.PubMed/NCBI
38	Ozer H, Boztosun A, Acmaz G, Atilgan R, Akkar OB and Kosar MI: The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model. Reprod Sci. 20:26–32. 2013. View Article : Google Scholar : PubMed/NCBI
39	Machado DE, Abrao MS, Berardo PT, Takiya CM and Nasciutti LE: Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril. 90:148–155. 2008. View Article : Google Scholar : PubMed/NCBI
40	McLaren J, Prentice A, Charnock-Jones DS and Smith SK: Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod. 11:220–223. 1996. View Article : Google Scholar : PubMed/NCBI
41	Donnez J, Smoes P, Gillerot S, Casanas-Roux F and Nisolle M: Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod. 13:1686–1690. 1998. View Article : Google Scholar : PubMed/NCBI
42	Dela Cruz C and Reis FM: The role of TGFβ superfamily members in the pathophysiology of endometriosis. Gynecol Endocrinol. 31:511–515. 2015. View Article : Google Scholar : PubMed/NCBI
43	Zhang Q, Duan J, Liu X and Guo SW: Platelets drive smooth muscle metaplasia and fibrogenesis in endometriosis through epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation. Mol Cell Endocrinol. 428:1–16. 2016. View Article : Google Scholar : PubMed/NCBI
44	Rein DT, Schmidt T, Bauerschmitz G, Hampl M, Beyer IM, Paupoo AA, Curiel DT and Breidenbach M: Treatment of endometriosis with a VEGF-targeted conditionally replicative adenovirus. Fertil Steril. 93:2687–2694. 2010. View Article : Google Scholar : PubMed/NCBI
45	Mohamed ML, El Behery MM and Mansour SA: Comparative study between VEGF-A and CA-125 in diagnosis and follow-up of advanced endometriosis after conservative laparoscopic surgery. Arch Gynecol Obstet. 287:77–82. 2013. View Article : Google Scholar : PubMed/NCBI
46	Perini JA, Cardoso JV, Berardo PT, Vianna-Jorge R, Nasciutti LE, Bellodi-Privato M, Machado DE and Abrão MS: Role of vascular endothelial growth factor polymorphisms (−2578C>A, −460 T>C, −1154G>A, +405G>C and +936C>T) in endometriosis: A case-control study with Brazilians. BMC Womens Health. 14:1172014. View Article : Google Scholar : PubMed/NCBI
47	Tamburro S, Canis M, Albuisson E, Dechelotte P, Darcha C and Mage G: Expression of transforming growth factor beta1 in nerve fibers is related to dysmenorrhea and laparoscopic appearance of endometriotic implants. Fertil Steril. 80:1131–1136. 2003. View Article : Google Scholar : PubMed/NCBI
48	Huang HF, Hong LH, Tan Y and Sheng JZ: Matrix metalloproteinase 2 is associated with changes in steroid hormones in the sera and peritoneal fluid of patients with endometriosis. Fertil Steril. 81:1235–1239. 2004. View Article : Google Scholar : PubMed/NCBI
49	Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med. 6:389–395. 2000. View Article : Google Scholar : PubMed/NCBI
50	Bulun SE: Endometriosis. N Engl J Med. 360:268–279. 2009. View Article : Google Scholar : PubMed/NCBI
51	Burney RO and Giudice LC: Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 98:511–519. 2012. View Article : Google Scholar : PubMed/NCBI
52	Bulun SE, Zeitoun KM, Takayama K and Sasano H: Molecular basis for treating endometriosis with aromatase inhibitors. Hum Reprod Update. 6:413–418. 2000. View Article : Google Scholar : PubMed/NCBI
53	Abu Hashim H: Potential role of aromatase inhibitors in the treatment of endometriosis. Int J Womens Health. 6:671–680. 2014.PubMed/NCBI
54	Ailawadi RK, Jobanputra S, Kataria M, Gurates B and Bulun SE: Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: A pilot study. Fertil Steril. 81:290–296. 2004. View Article : Google Scholar : PubMed/NCBI
55	Abushahin F, Goldman KN, Barbieri E, Milad M, Rademaker A and Bulun SE: Aromatase inhibition for refractory endometriosis-related chronic pelvic pain. Fertil Steril. 96:939–942. 2011. View Article : Google Scholar : PubMed/NCBI
56	Oner G, Ozcelik B, Ozgun MT, Serin IS, Ozturk F and Basbug M: The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model. Hum Rep. 25:932–937. 2010. View Article : Google Scholar
57	Li X, Kang X, Deng Q, Cai J and Wang Z: Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: A controlled experimental animal study. Reprod Biol Endocrinol. 11:162013. View Article : Google Scholar : PubMed/NCBI
58	Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M and Haim N: Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod. 11:1620–1626. 1996. View Article : Google Scholar : PubMed/NCBI
59	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
60	Ruggiero A, Trombatore G, Triarico S, Arena R, Ferrara P, Scalzone M, Pierri F and Riccardi R: Platinum compounds in children with cancer: Toxicity and clinical management. Anticancer Drugs. 24:1007–1019. 2013. View Article : Google Scholar : PubMed/NCBI
61	Chahvar ST, Al-Shawaf T and Tranquilli AL: Pharmacologic ovarian preservation in young women undergoing chemotherapy. Curr Med Chem. 21:223–229. 2014. View Article : Google Scholar : PubMed/NCBI